Skip to main content

Table 3 Summary of efficacy measures

From: Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study

 

Everolimus 10 mg/day, N = 64

PFS

 

   PFS events, n (%)

35 (55)

     Progression

26 (41)

     Death

9 (14)

   Censored observations, n (%)

29 (45)

Median PFS, months (95% CI)

6.9 (3.7-12.5)

Best Overall Response, n (%)

 

   Complete response

0

   Partial response

3 (5)

   Stable disease

39 (61)

   Progressive disease

8 (13)

   Unknown*

14 (22)

Response analysis, n (%)

 

   ORR (CR or PR)

3 (5)

   [95% CI for ORR]

[1–13]

   DCR (CR or PR or SD)

42 (66)

   [95% CI for DCR]

[53–77]

OS

 

   Median OS, months (95% CI)

NR (10.7-NR)

   Probability of OS at 6 months,% (95% CI)

76 (64–85)

   Probability of OS at 12 months,% (95% CI)

56 (42–68)

  1. *Includes patients with no tumor assessments.
  2. PFS, progression-free survival; ORR, overall response rate; OS, overall survival; CR, complete response; PR, partial response, SD, stable disease; NR, not reached.